Ken Griffin Hille Vax, Inc. Transaction History

Citadel Advisors LLC

$550 Billion
Q2 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Hille Vax, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 30,196 shares of HLVX stock, worth $62,807. This represents 0.0% of its overall portfolio holdings.

Number of Shares

30,196

Holding current value

$62,807

% of portfolio

0.0%

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$1.39 - $2.04 $41,972 - $61,599	30,196 New	30,196 $60,000
Q4 2024 Feb 14, 2025	SELL	$1.72 - $2.06 $98,155 - $117,558	-57,067 Reduced 32.52%	118,400 $241,000
Q3 2024 Nov 14, 2024	SELL	$1.58 - $14.42 $563,036 - $5.14 Million	-356,352 Reduced 67.01%	175,467 $308,000
Q2 2024 Aug 14, 2024	SELL	$11.86 - $15.93 $1.39 Million - $1.87 Million	-117,557 Reduced 18.1%	531,819 $7.69 Million
Q1 2024 May 15, 2024	SELL	$14.15 - $19.75 $1.06 Million - $1.48 Million	-75,000 Reduced 10.35%	649,376 $10.8 Million
Q4 2023 Feb 14, 2024	SELL	$10.35 - $17.11 $1.48 Million - $2.44 Million	-142,837 Reduced 16.47%	724,376 $11.6 Million
Q3 2023 Nov 14, 2023	BUY	$11.59 - $16.7 $10.1 Million - $14.5 Million	867,213 New	867,213 $11.7 Million

Others Institutions Holding HLVX

# of Institutions

Shares Held

36.1M

Call Options Held

Put Options Held

Frazier Life Sciences Management, L.P. Menlo Park, CA

10.6M
Shares

$22.1 Million
1.11% of portfolio
Tang Capital Management LLC San Diego, CA

4.92M
Shares

$10.2 Million
0.59% of portfolio
Eco R1 Capital, LLC San Francisco, CA

2.42M
Shares

$5.03 Million
0.41% of portfolio
Black Rock Inc. New York, NY

2.09M
Shares

$4.35 Million
0.0% of portfolio
Franklin Resources Inc San Mateo, CA

1.95M
Shares

$4.06 Million
0.0% of portfolio

View Full List

About HilleVax, Inc.

Ticker HLVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,427,200
Market Cap $69.5M
Description
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

More about HLVX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account